Oric Pharmaceuticals (NASDAQ:ORIC) Sets New 12-Month High – Here’s What Happened

Posted by Geri Gentry on Aug 22nd, 2026

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) hit a new 52-week high during trading on Thursday . The stock traded as high as $15.00 and last traded at $14.4240, with a volume of 379 shares. The stock had previously closed at $14.65.

Analyst Upgrades and Downgrades

ORIC has been the topic of a number of recent analyst reports. Benchmark reissued a “buy” rating on shares of Oric Pharmaceuticals in a report on Monday, June 8th. Citigroup cut their price target on Oric Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating for the company in a report on Tuesday, May 5th. The Goldman Sachs Group raised shares of Oric Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $15.00 price objective for the company in a research report on Friday, May 15th. Wall Street Zen upgraded shares of Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, July 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research report on Friday, July 17th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $19.45.

View Our Latest Stock Report on ORIC

Oric Pharmaceuticals Stock Up 2.3%

The business has a fifty day moving average price of $11.34 and a 200-day moving average price of $10.62. The company has a market cap of $1.47 billion, a P/E ratio of -10.52 and a beta of 1.02.

Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.02). As a group, research analysts expect that Oric Pharmaceuticals, Inc. will post -1.53 earnings per share for the current year.

Institutional Investors Weigh In On Oric Pharmaceuticals

A number of institutional investors have recently modified their holdings of ORIC. Federation des caisses Desjardins du Quebec increased its position in Oric Pharmaceuticals by 100.0% during the fourth quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company’s stock worth $33,000 after acquiring an additional 2,000 shares during the period. Caitong International Asset Management Co. Ltd boosted its holdings in Oric Pharmaceuticals by 184.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,528 shares of the company’s stock valued at $37,000 after purchasing an additional 2,936 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Oric Pharmaceuticals by 26.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company’s stock valued at $39,000 after purchasing an additional 977 shares during the period. Quantbot Technologies LP acquired a new position in shares of Oric Pharmaceuticals during the 2nd quarter worth approximately $46,000. Finally, Russell Investments Group Ltd. acquired a new position in shares of Oric Pharmaceuticals during the 3rd quarter worth approximately $60,000. Institutional investors own 95.05% of the company’s stock.

About Oric Pharmaceuticals

(Get Free Report)

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.